Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.12  Related to the article below (Last Update: 8/4/2008)


Earthtimes (press release)
Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
Anadarko Announces Second-Quarter Results WELT ONLINE
TheStreet.com Reports Second-Quarter Financial Results MarketWatch
Conexant Reports Financial Results for the Third Quarter of Fiscal ... Trading Markets (press release)
CNNMoney.com (press release) - MarketWatch
all 1,205 news articles »  CNXTD - FISV - APC

Space Ref (press release)
NASA OIG Audit of International Space Station Contracts Government ...
Space Ref (press release) -
While the total dollar value negotiated was minor [$260330 of $213977647 (0.12 percent) or $2065311 projected to the entire population], the documentation ...
Fisher Communications, Inc. Reports Second Quarter Financial ...
MarketWatch - Jul 31, 2008
A live audio webcast of the call will be accessible to the public on Fisher's Web site, www.fsci.com. A recording of the webcast will subsequently be ...FSCI - SAF
June 2008 - Quarterly Activities Report
Sydney Morning Herald, Australia - Jul 30, 2008
... results including: KB-1 Magmatic Copper-Nickel Target - 2.57% Cu, 0.12% Ni - 1.88% Cu, 0.12% Ni KB-2 Gold-Silver / Base Metals Target - 31.2 g/t Au, ...ASX:WMT - LON:URA
Belo Reports Results for Second Quarter 2008
FOXBusiness - Jul 25, 2008
Advertising revenue associated with Belo's Web sites increased 7.3 percent to $7.5 million in the second quarter 2008, representing 4 percent of Belo's ...
Superior Uniform Group Reports Continued Improvement in Operating ... MarketWatch
all 179 news articles »  SGC - BLC - OTC:CMTX
Tasty Baking Company Reports Second Quarter 2008 Results
MarketWatch - Aug 1, 2008
Investors will have the opportunity to listen to the call over the Internet at Tasty Baking Company's web site, http://www.tastykake.com. ...TSTY
Mercer International Inc. Reports 2008 Second Quarter Results
Stockhouse, Canada - Jul 30, 2008
In the first half of 2007, we reported net income from continuing operations of euro 4.4 million, or euro 0.12 per basic and diluted share. ...MERC

FLEXNEWS
Caraustar Industries, Inc. Reports Second Quarter Results
Earthtimes (press release), UK - Aug 1, 2008
These documents may be accessed through the web site of the Securities and Exchange Commission (www.sec.gov). The company does not undertake any obligation ...
Kaydon Corporation Reports Second Quarter Results Barron's Blogs
Chiquita Reports Strong Second Quarter 2008 Results PR Newswire (press release)
Goodyear Reports Strong Second Quarter and First Half Results PR Newswire (press release)
all 907 news articles »  CQB - CSAR - GT

Earthtimes (press release)
Highwoods Properties Reports Second Quarter 2008 Results
Trading Markets (press release), CA - Jul 29, 2008
A live listen-only Web cast can be accessed through the Company's web site at www.highwoods.com under the "Investor Relations" section. ...
Cogdell Spencer Inc. Reports Second Quarter 2008 Financial Results Earthtimes (press release)
all 179 news articles »  HIW - CSA
Omniture Reports Second Quarter 2008 Financial Results
MarketWatch - Jul 23, 2008
The webcast will be available on the "Investor Relations" section of the company's corporate web site at www.omtr.com. A replay of the conference call will ...OMTR
Source: Google News

Copper coordination geometry in azurin undergoes minimal change on reduction of copper (II) to …
WEB Shepard, BF Anderson, DA Lewandoski, GE Norris … - Journal of the American Chemical Society, 1990 - pubs.acs.org
... Distance of Cu from Plane through N6,(46), Sy(ll2), and N6,(1 17). 8, 0.12 0.16
0.14 0.16 0.09 0.12 ' Bond distances and angles within the trigonal plane. ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle ... Docosanoic
0.35 (0.06) 0.41 (0.12) Hexacosanoic 0.64 (0.12) 0.83 (0.32) ...

A comparison of development effort estimation techniques for Web hypermedia applications -
E Mendes, I Watson, C Triggs, N Mosley, S Counsell - Software Metrics, 2002. Proceedings. Eighth IEEE Symposium …, 2002 - ieeexplore.ieee.org
... In the Web engineering literature, the adaptation used to date is the mean of the
closest analogies ... MMRE MdMRE Pred(25) Yes 0.12 0.10 88.24 1 Mean No 0.11 0.09

The ocean?s food web, a changing paradigm
LR Pomeroy - Bioscience, 1974 - JSTOR
... form the basis of the established paradigm of the food web, but nannoplankton ... 1971
Peru Current (Equador) 0.09 Malone 1971 E. tropical Pacific 0.12 Malone 1971 ...

[PDF] Removal policies in network caches for world-wide web documents -
S Williams, M Abrams, CR Strandridge, G Abdulla, E … - Computer Communication Review, 1996 - cs.kent.edu
... caching in networks with workloads like ours could dramat- ically reduce the load
on popular Web servers. ... CGI 0.13 0.08 0.15 0.12 0.12 0.03 0.22 0.00 0.95 0.05 ...
-

Regulation of Lake Primary Productivity by Food Web Structure -
SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR
... moved offshore immediately after release. December 1987 LAKE PRODUCTIVITY AND FOOD
WEB STRUCTURE 1871 in ... n = 9) than in 1984 (mean = 0.96 g/m2, SE -- 0.12, n = 9 ...

Effect of Scale on Food Web Structure -
ND Martinez - Science, 1993 - sciencemag.org
... Also in line with the convention, an eighth food web property, connectance, is inferred ...
0.057, R2 = 0.07), 1 = 0.284S + 33 (SEsiope = 0.110, R2 = 0.12), and B ...

[PDF] Phylogenetic constraints and adaptation explain food-web structure -
MF Cattin, LF Bersier, C Banasek-Richter, R … - Nature, 2004 - unifr.ch
... by one order of magnitude?in the prediction of these standard food-web descriptors ...
Lo 0.25 [0.12] 0.40 ? 0.05 [0] 0.13 0.00 [0.24] 0.02 0.01 [0] 0.06 0.26 [0 ...
-

[PDF] An Adaptive Agent for Web Exploration Based on Concept Hierarchies -
S Parent, B Mobasher, S Lytinen - Proceedings of the 9th International Conference on Human …, 2001 - maya.cs.depaul.edu
... On the other hand, a user interested in searching the Web for specific medical ... music:
1.000 blue: 0.15 new: 0.14 artist: 0.13 jazz: 0.12 review: 0.12 band ...

Production of Dimethylsulfonium Propionate (DMSP) and Dimethylsulfide (DMS) by a Microbial Food Web -
SK Kim, F Rassoulzadegan, B Krajka, BC Nguyen, N … - Limnology and Oceanography, 1990 - JSTOR
... we calcu- lated it with a constant DMS loss through the membranes (0.12 nM hl). ... that
decomposition of DMSP into DMS in the microbial food web involves several ...

Source: Google Scholar
 
 

Biolex Reports Potential For More Potent, Efficacious Antibodies In Nature Biotechnology

Article Date: 30 Nov 2006 - 16:00pm (PST)
Biolex Therapeutics have announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX SystemSM to produce monoclonal antibodies that have enhanced in vitro potency and efficacy. The research was conducted by scientists from Biolex and Medarex as part of an ongoing collaboration between the two companies. The publication also describes the LEX System's ability to produce antibodies with homogeneous glycosylation structures, an additional major advantage of the LEX System compared to expression systems commonly used today and key to reducing production risks, regulatory risks and costs.

"The rapid and successful evolution of our ability to optimize monoclonal antibodies greatly enhances the value of the LEX System and has expanded our commercialization opportunities," said Mr. Jan Turek, Biolex Chief Executive Officer. "Antibody glycosylation optimization is the focal point of a number of our current and future expected collaborations, and provides us with additional opportunities for expansion of Biolex's own proprietary pipeline."

Results Reported in Nature Biotechnology

Monoclonal antibodies comprise one of the fastest growing classes of protein therapeutics and are currently being used and developed primarily to treat cancers, autoimmune diseases, infectious diseases and inflammatory diseases. The effectiveness of monoclonal antibodies, particularly those targeting oncology indications, are greatly impacted by the glycosylation, or sugar chain, structure of the antibody's Fc region. The majority of monoclonal antibodies are currently produced in a mammalian cell system, specifically systems utilizing cultured Chinese hamster ovary (CHO) cells.

Article continues below and (thank you)
 
Results were reported online on November 26 and in the December print issue of Nature Biotechnology, under the title "Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor." Scientists at Medarex and Biolex characterized the monoclonal antibody MDX-060 produced in the LEX System and MDX-060 produced in a CHO system. The LEX System was engineered by Biolex to optimize the glycosylation structure of the antibody. MDX-060 produced in the LEX System had higher affinity for Fc receptors than MDX-060 produced in the CHO system, an attribute that, in other antibody products, has been strongly correlated with increased efficacy and response to treatment in oncology and autoimmune indications. The binding affinity of the LEX System MDX-060 was at least 20 to 35 times higher than MDX-060 produced in the CHO system, and the effector function of the LEX System MDX-060 was at least double that of the CHO system MDX-060, measured by comparing antibody dependent, cell-mediated cytotoxicity (ADCC).

The optimization of MDX-060 was achieved by engineering the LEX System to silence two genes responsible for adding two specific sugars, fucose and xylose, to the glycosylation structure of the antibody. Fucose is a sugar typically present in the glycosylation structure of monoclonal antibodies produced in existing expression systems. The improved Fc functionality demonstrated for MDX-060 produced in the LEX System resulted from the fact that the system was successful in expressing the antibody with a glycosylation structure that excluded fucose. Biolex's success in eliminating the expression of fucose as well as another sugar, xylose, resulted in a fully human glycosylation structure completely devoid of any detectable presence of fucose or xylose. Biolex has successfully produced more than ten monoclonal antibodies, and the ability of the LEX System to produce optimized antibodies with fully human glycosylation (i.e., with no fucose or xylose) has been demonstrated with multiple partners and in multiple proteins, highlighting the robustness and consistency of the system.

MDX-060 is a monoclonal antibody currently under development by Medarex. The studies described in the publication were undertaken as part of a collaboration between Biolex and Medarex initiated in 2005 and expanded earlier this year. Under the collaboration, Biolex has employed the LEX System to develop commercial lines for three Medarex antibodies.

"We are pleased with the rapid progress our collaboration with Biolex has achieved to date," said Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex. "We look forward to applying this technology to enhance the development of potentially effective antibody therapeutics."

Homogeneity of LEX System is Unprecedented

The results reported in the publication also demonstrate that the LEX System produces antibodies with a homogeneous glycosylation structure, distinguishing the LEX System from the limited number of other technologies that have been described for reducing monoclonal antibody fucosylation in CHO and other expression systems. MDX-060 was produced in the LEX System as a single, highly desirable, fully human glycoform. By contrast, CHO systems using other glycosylation engineering technologies are reported to express antibodies as a heterogeneous mixture of glycoforms. The proportion of specific glycoforms produced by a CHO system can change with cell culture conditions, production scale and other variables, making characterization of the antibody difficult and creating potential consistency, scale-up and regulatory challenges. Accordingly, the ability of the LEX System to produce antibodies with homogeneous glycosylation, without the need for further post-expression chemical modification is unprecedented and represents a major advancement. Furthermore, engineering the LEX System to achieve this optimized glycosylation does not result in a loss of production efficiency or yields.

"Controlling glycosylation and achieving consistent production throughout scale-up is a significant challenge that faces the biopharmaceutical industry," said David Spencer, Ph.D., Biolex Chief Operating Officer and Senior Vice President, Research and Development. "The ability of the LEX System to produce antibodies with greater functionality and homogeneous glycosylation is a major achievement."

###


 
About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on its proprietary LEX System, an expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead candidate, Locteronâ„¢, is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C. The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, catheter occlusion and deep vein thrombosis. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture-capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at http://www.biolex.com/.

Contact: Michelle Linn
Linnden Communications
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page